article thumbnail

Cholesterol Med, Fenofibrate, Might Slow Vision Loss in People With Diabetes

Drugs.com

TUESDAY, June 25, 2024 -- A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows. Fenofibrate (Tricor) has been approved since 2004 as a means of lowering.

Trials 279
article thumbnail

Cholesterol Med Might Slow Vision Loss in People With Diabetes

Drugs.com

TUESDAY, June 25, 2024 -- A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows.Fenofibrate (Tricor) has been approved since 2004 as a means of lowering.

Trials 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ensuring Your Organization is Prepared for the Implementation of the EU Clinical Trial Regulation

PPD

The European Union Clinical Trial Regulation (EU CTR) brings the biggest change in the regulatory landscape since the implementation of the EU Clinical Trials Directive in 2004, requiring vast changes in the way organizations are structured and conduct their day-to-day activities.

article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

2 However, when dosed at the MTD, ADCs display improved efficacy over small molecules in oncology trials. Whilst no trials have been performed directly comparing small molecules with their ADC counterparts, it is possible to contrast data from trials with ADCs to those performed with analogous small molecules.

article thumbnail

Advancing reduction of drug use as an endpoint in addiction treatment trials

National Institute on Drug Abuse: Nora's Blog

Advancing reduction of drug use as an endpoint in addiction treatment trials astewart Thu, 03/06/2025 - 09:59 Nora's Blog March 18, 2025 Image Getty Images/ SolStock This blog was also published in the American Society of Addiction Medicine (ASAM) Weekly on March 18, 2025.&

article thumbnail

Stem cell therapy to slow progression of multiple sclerosis (MS)

Drug Target Review

This study sought to shed light on the safety and effectiveness of aHSCT in routine healthcare settings, moving beyond the confines of clinical trials. This aligns with results observed in the only randomised controlled trial conducted thus far.

Therapies 116
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

Up until 2023 around 600 NK cell clinical trials have been reported and some 200 are clinically active and still recruiting patients. The vast majority (65/74; 88%) of those trials involved NK cells without CARs; while only 12 percent were CAR-NK studies. CAR-NK cell trials only commenced in 2017 and most are still recruiting patients.

Therapies 118